✦ LIBER ✦

Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias

✍ Scribed by Mughal, Tariq I.

Book ID: 122396361
Publisher: CIG Media Group, LP.
Year: 2006
Tongue: English
Weight: 105 KB
Volume: 1
Category: Article
ISSN: 1931-6925
DOI: 10.3816/CLK.2006.n.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of Tyrosine Kinase Inhibitors in th

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

✍ Michael S. Mathisen; Susan O’Brien; Deborah Thomas; Jorge Cortes; Hagop Kantarji 📂 Article 📅 2011 🏛 Current Science Inc. 🌐 English ⚖ 152 KB

Treatment of Philadelphia-chromosome-pos

Treatment of Philadelphia-chromosome-positive human leukemia in scid mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor

✍ Yoshio Honma; Yoshinobu Matsuo; Yasuhide Hayashi; Satoshi Omura 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 731 KB

The molecular basis of the Philadelphia chromosome (Ph') is a structurally altered c-abl (bcr-abl) gene which encodes an abnormally large protein with protein tyrosine kinase activity. Herbimycin A, which effectively reduced intracellular phosphorylation by bcr-abl tyrosine kinase, preferentially in

Phase 1 study of INNO-406, a dual Abl/Ly

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

✍ Hagop Kantarjian; Phillipp le Coutre; Jorge Cortes; Javier Pinilla-Ibarz; Arnon 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB

Dasatinib Resistance in Patients with Ch

Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation

✍ Krijanovski, Yelena; Donato, Nicholas; Sun, Hanshi; Meng, Feng; Quintás-Cardama, 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 105 KB

Novel aspects of therapy with the dual S

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia

✍ Keller-v.Amsberg, Gunhild ;Brümmendorf, Tim H 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 672 KB

ABL-specific tyrosine kinase inhibitor i

ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)

✍ Selle, B; Bär, C; Hecker, S; Schmidt-Rohr, U; Viehmann, S; Debatin, K-M; Reinhar 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 146 KB